-
Je něco špatně v tomto záznamu ?
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease
H. Theis, N. Pavese, I. Rektorová, T. van Eimeren
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2023
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
38339941
DOI
10.3233/jpd-230385
Knihovny.cz E-zdroje
- MeSH
- biologické markery * metabolismus analýza MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- neurozobrazování metody MeSH
- optická koherentní tomografie metody MeSH
- Parkinsonova nemoc * diagnostické zobrazování metabolismus diagnóza MeSH
- pozitronová emisní tomografie MeSH
- prodromální symptomy * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET tracers to assess degeneration of the dopaminergic system are available. Furthermore, metabolic PET patterns can be used to anticipate a phenoconversion from prodromal PD to manifest PD. In this regard, it is worth mentioning that PET imaging of inflammation will gain significance. Molecular imaging of neurotransmitters like serotonin, noradrenaline and acetylcholine shed more light on non-motor symptoms. Outside of the brain, molecular imaging of the heart and gut is used to measure PD-related degeneration of the autonomous nervous system. Moreover, optical coherence tomography can noninvasively detect degeneration of retinal fibers as a potential biomarker in PD. In this review, we describe these state-of-the-art imaging modalities in early and prodromal PD and point out in how far these techniques can and will be used in the future to pave the way towards a biomarker-based staging of PD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004206
- 003
- CZ-PrNML
- 005
- 20250206110016.0
- 007
- ta
- 008
- 250121s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/JPD-230385 $2 doi
- 035 __
- $a (PubMed)38339941
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Theis, Hendrik $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Multimodal Neuroimaging Group, Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany
- 245 10
- $a Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease / $c H. Theis, N. Pavese, I. Rektorová, T. van Eimeren
- 520 9_
- $a Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET tracers to assess degeneration of the dopaminergic system are available. Furthermore, metabolic PET patterns can be used to anticipate a phenoconversion from prodromal PD to manifest PD. In this regard, it is worth mentioning that PET imaging of inflammation will gain significance. Molecular imaging of neurotransmitters like serotonin, noradrenaline and acetylcholine shed more light on non-motor symptoms. Outside of the brain, molecular imaging of the heart and gut is used to measure PD-related degeneration of the autonomous nervous system. Moreover, optical coherence tomography can noninvasively detect degeneration of retinal fibers as a potential biomarker in PD. In this review, we describe these state-of-the-art imaging modalities in early and prodromal PD and point out in how far these techniques can and will be used in the future to pave the way towards a biomarker-based staging of PD.
- 650 12
- $a Parkinsonova nemoc $x diagnostické zobrazování $x metabolismus $x diagnóza $7 D010300
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a prodromální symptomy $7 D062706
- 650 12
- $a biologické markery $x metabolismus $x analýza $7 D015415
- 650 _2
- $a optická koherentní tomografie $x metody $7 D041623
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a neurozobrazování $x metody $7 D059906
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Pavese, Nicola $u Aarhus University, Institute of Clinical Medicine, Department of Nuclear Medicine & PET, Aarhus N, Denmark $u Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom
- 700 1_
- $a Rektorová, Irena $u Masaryk University, Faculty of Medicine and St. Anne's University Hospital, International Clinical Research Center, ICRC, Brno, Czech Republic $u Masaryk University, Faculty of Medicine and St. Anne's University Hospital, First Department of Neurology, Brno, Czech Republic $u Masaryk University, Applied Neuroscience Research Group, Central European Institute of Technology - CEITEC, Brno, Czech Republic
- 700 1_
- $a van Eimeren, Thilo $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Multimodal Neuroimaging Group, Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany
- 773 0_
- $w MED00208289 $t Journal of Parkinson's disease $x 1877-718X $g Roč. 14, s2 (2024), s. S353-S365
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38339941 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206110012 $b ABA008
- 999 __
- $a ok $b bmc $g 2263756 $s 1240213
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c s2 $d S353-S365 $e - $i 1877-718X $m Journal of Parkinson's disease $n J Parkinsons Dis $x MED00208289
- LZP __
- $a Pubmed-20250121